Tammie L.S. Benzinger

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex

Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia

Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease

The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease

Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests

A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests

Brain aging patterns in a large and diverse cohort of 49,482 individuals

Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease

Genetic and Clinical Correlates of AI-Based Brain Aging Patterns in Cognitively Unimpaired Individuals

Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease

Genetic and clinical correlates of two neuroanatomical AI dimensions in the Alzheimer’s disease continuum

Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals

Relationship between MRI brain-age heterogeneity, cognition, genetics and Alzheimer’s disease neuropathology

Cognitive reserve influences symptom onset and longitudinal decline in Dominantly Inherited Alzheimer's Disease

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer’s disease

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease

Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease

Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)

Alzheimer Disease Pathology and Neurodegeneration in Midlife Obesity: A Pilot Study

Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease

Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimer’s Disease

Identifying individuals with non‐Alzheimer's disease co‐pathologies: A precision medicine approach to clinical trials in sporadic Alzheimer's disease

Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals